成人小说亚洲一区二区三区,亚洲国产精品一区二区三区,国产精品成人精品久久久,久久综合一区二区三区,精品无码av一区二区,国产一级a毛一级a看免费视频,欧洲uv免费在线区一二区,亚洲国产欧美中日韩成人综合视频,国产熟女一区二区三区五月婷小说,亚洲一区波多野结衣在线

立即打開(kāi)
新藥備受爭(zhēng)議,但這家公司卻仍不放棄

新藥備受爭(zhēng)議,但這家公司卻仍不放棄

Sussie Gharib 2019-12-17
公司的首席執(zhí)行官稱,在服用了渤健藥物18個(gè)月后,阿爾茨海默病的患者出現(xiàn)了“明顯的”好轉(zhuǎn)跡象。

有關(guān)渤?。˙iogen)和其引發(fā)爭(zhēng)議的治療阿爾茨海默病的藥物,將有更多好戲上演。在加州圣迭戈面對(duì)一大群研究阿爾茨海默病的科學(xué)家時(shí),渤健展示了其名為aducanumab藥物的新數(shù)據(jù),稱這種藥物可以緩解阿爾茨海默病患者的癥狀。在詳細(xì)的闡述中,公司稱臨床試驗(yàn)顯示,使用該藥物最高劑量的患者,在認(rèn)知能力的退化方面要比服用無(wú)效對(duì)照劑的患者更加緩慢。

今年10月,渤健宣布重新啟動(dòng)該藥物研究,并將尋求監(jiān)管機(jī)構(gòu)許可,震驚了整個(gè)生物醫(yī)藥界,此后也引來(lái)了諸多的懷疑。因?yàn)閹讉€(gè)月前,渤健曾經(jīng)宣布放棄推出該藥物,并終止對(duì)該藥物的研究,因?yàn)樵囼?yàn)結(jié)果令人失望。

如今,這家位于馬薩諸塞州劍橋市的生物科技公司稱,這一藥物有效,他們已經(jīng)重拾信心,并已經(jīng)向美國(guó)食品與藥品管理局申請(qǐng)?jiān)S可。申請(qǐng)結(jié)果預(yù)計(jì)將在2020年公布。如果監(jiān)管機(jī)構(gòu)同意,那么該藥物將成為能夠?qū)嶋H幫助日益衰弱的阿爾茨海默病患者的首種藥物。

隨著故事的起伏,渤健的股價(jià)也隨著每條新消息漲漲跌跌,而華爾街也是莫衷一是。

當(dāng)我在幾周前與渤健的首席執(zhí)行官米格爾·維納特索斯對(duì)話時(shí),他顯得積極而充滿信心。他說(shuō),他覺(jué)得令人鼓舞的是,阿爾茨海默病的患者在服用了渤健藥物18個(gè)月后,出現(xiàn)了“明顯的”好轉(zhuǎn)跡象。

“我們要誠(chéng)實(shí)、謙虛,并遵守監(jiān)管流程?!彼f(shuō),“在慶祝之前,我們得先等一等。但確實(shí)有希望?!?/p>

那么,如果維納特索斯成功地將這款突破性的治療阿爾茨海默病的新藥推向市場(chǎng),它的售價(jià)將是多少呢?一開(kāi)始,他推脫說(shuō):“談價(jià)格還太早?!?/p>

考慮再三后,他提議說(shuō),這種藥物投放市場(chǎng)后,將采用一種更加有創(chuàng)意的支付方式,用以覆蓋數(shù)百萬(wàn)因?yàn)榘柎暮D《鴨适в洃浀幕颊?。?jù)美國(guó)疾控中心的數(shù)據(jù),在美國(guó)患有阿爾茨海默病的患者人數(shù),到2060年時(shí)將翻兩番,達(dá)到1400萬(wàn)人。

“這需要多方努力以及政府參與,”他說(shuō),“我們公司和管理層,將對(duì)創(chuàng)新的商業(yè)方式也保持開(kāi)放態(tài)度,讓藥物治療覆蓋更多的人群。我將竭盡所能破除那種舊式的繳費(fèi)才治療的模式,這種模式在治療大范圍人群時(shí)已經(jīng)顯示出局限性?!保ㄘ?cái)富中文網(wǎng))

譯者:宣峰

There was more drama this week about Biogen and its controversial Alzheimer’s drug. Speaking before a large crowd of Alzheimer scientists gathered in San Diego, California, Biogen showed new data that its drug, called aducanumab, could offer relief to people struggling with Alzheimer’s. In a detailed presentation, the company said that in clinical trials, patients receiving the highest dose of the drug had slower declines in their cognitive abilities than patients who received a placebo.

There’s been plenty of skepticism about those claims ever since Biogen shocked the biotech world in October when it announced it was resurrecting its research and would also seek regulatory approval for the drug. Just a few months earlier, Biogen said it had given up on aducanumab and terminated its research because of disappointing results.

Now the Cambridge, Massachusetts-based biotechnology company says it has renewed confidence that the drug works and has returned to the Food and Drug Administration for approval. A decision is expected in 2020. If regulators give the okay, the drug could be the first treatment that actually helps people with the debilitating Alzheimer’s disease.

As the saga continues, Biogen shares have been soaring and tumbling on every new piece of information, and opinions on Wall Street have been mixed.

But when I spoke with Biogen CEO Michel Vounatsos a few weeks ago, he was positive and hopeful. What he finds encouraging, he says, is that Alzheimer’s patients who have received Biogen’s drug treatment showed “significant” improvement after 18 months.

“We have to be modest, humbled, and follow the regulatory process now,” he tells me. “We have to wait before we celebrate. But there is hope.”

So, if Vounatsos succeeds in delivering a breakthrough drug to treat Alzheimer’s, what will it cost? At first, he pushes back saying, “it’s too early to speak about cost.”

After some thought, he suggests that it will take a more innovative payment model to cover the millions of people suffering from Alzheimer’s memory loss. According to the CDC, the number of people living with Alzheimer’s disease is expected to nearly triple to 14 million people in the United States by 2060.

“This will take multi-party and engagement with authorities,” he says. “And the company and its leadership will be open to innovative contracting in order to treat the larger population. I will do everything I can in order to disrupt from the old models of fee-for-service that have certainly demonstrated their limitation in terms of treating a broader population. ”

掃描二維碼下載財(cái)富APP
抱姝姝a片亚洲综合久久国产| 在线观看无码国产精品午夜无码一级| 亚洲国产AV无码一区二区三区| 精品国产高清一区二区广区| 国产日韩在线亚洲字幕中文| 午夜日韩欧美电影在线观看| 日韩精品无码一本二本三本色| 欧美 亚洲 有码中文字幕| 久久国产精品成人免费秋霞| 激情国产原创在线观看| 人人超碰人人爱超碰国产| 三级全黄的视频在线观看| 国产精品久久久久久久久鸭| 亚洲精品A片久久久久| 奇米777狠狠色嚕嚕狠狠狠| 日本乱人伦aⅴ精品| 国产蹂躏精品免费| 亚洲精品WWW久久久久久| 国产午夜电影在线观看| 国产麻豆天美果冻无码视频| 久久不见久久见免费影院www日本| 亚洲A∨精品一区二区三区| 午夜av精品一区二区三区| 97se狠狠狠狠狼鲁亚洲综合色| 人妻少妇精品无码专区二区a| 国产成人AV无码永久免费一线天| 欧美激情欧美精品一区二区| 91偷拍自产一区二区三区| 国产一区二区三区无码视频| 久久这里只有精品视频9| 亚洲国产天堂在线观看| 国产精品女人高潮毛片| 日韩性人妻诱慰无码| 亚洲熟妇无码一区二区三区导航| 国产美女久久久亚洲综合| 精品无码一区二区三区 | 无码国模国产在线观看| 久久无码精品一区二区三区| 一本色道久久88加勒比—综合| 久人人爽人人爽人人片av| 亚洲欧美日韩综合久久|